Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Select Medical Holdings (SEM) Short-Term Debt issuances (2018 - 2025)

Select Medical Holdings (SEM) has disclosed Short-Term Debt issuances for 7 consecutive years, with $320.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Short-Term Debt issuances fell 74.52% to $320.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 billion, a 4.03% increase, with the full-year FY2025 number at $1.3 billion, up 4.03% from a year prior.
  • Short-Term Debt issuances was $320.0 million for Q4 2025 at Select Medical Holdings, up from $200.0 million in the prior quarter.
  • In the past five years, Short-Term Debt issuances ranged from a high of $1.3 billion in Q4 2024 to a low of -$855.4 million in Q4 2022.
  • A 5-year average of $150.6 million and a median of $200.0 million in 2025 define the central range for Short-Term Debt issuances.
  • Biggest YoY gain for Short-Term Debt issuances was 448507.5% in 2024; the steepest drop was 48640.07% in 2024.
  • Select Medical Holdings' Short-Term Debt issuances stood at $42.4 million in 2021, then crashed by 2119.67% to -$855.4 million in 2022, then surged by 100.03% to $280000.0 in 2023, then skyrocketed by 448507.5% to $1.3 billion in 2024, then plummeted by 74.52% to $320.0 million in 2025.
  • Per Business Quant, the three most recent readings for SEM's Short-Term Debt issuances are $320.0 million (Q4 2025), $200.0 million (Q3 2025), and $365.0 million (Q2 2025).